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Background: Clopidogrel has been widely used to prevent recurrent ischemia in patients with acute coronary syndrome (ACS). 
However, inter-individual variability in response to clopidogrel has been a problem in the clinical setting. The aim of the present 
study was to investigate the frequency of clopidogrel resistance and to determine the clinical, pharmacokinetic, and pharmacoge-
netic factors for clopidogrel resistance in Korean patients with ACS.
Methods: Clinical information, such as the underlying diseases and concurrent medications, of 114 patients with ACS who received 
clopidogrel therapy was studied. The degree of inhibition of platelets was assessed using the VerifyNow assay (Accumetrics, USA). 
The patients who showed less than 20% inhibition of platelets were defined as non-responders to clopidogrel treatment. Steady 
state plasma concentrations of clopidogrel were measured using HPLC/tandem mass spectrometry. CYP2C19 genotyping was also 
performed.
Results: A wide inter-individual variability was observed in platelet inhibition (0–76%); 56 patients (49%) showed less than 20% inhi-
bition. There were no differences between the patients’ history of diabetes mellitus and concurrent medications as well as the plas-
ma concentrations of clopidogrel of the responders and non-responders. CYP2C19 variants, including CYP2C19*2 and CYP2C19*3, 
were more commonly observed in the non-responders than in the responders (P value<0.0001).
Conclusions: The response to clopidogrel was highly variable in Korean patients with ACS. The results of the present study confirm-
ed that the genetic polymorphism of CYP2C19 could be important in clopidogrel response. However, further studies are required to 
investigate other likely factors involved in clopidogrel resistance.
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INTRODUCTION
Platelet activation and aggregation are the underlying 
pathophysiological mechanisms associated with acute coro-
nary syndrome (ACS) and other ischemic conditions. Clop-
idogrel has been recommended as an antiplatelet agent for 
the prevention of recurrent ischemic events. It is a prodrug 
that is converted to an active metabolite by the hepatic cyto-
chrome P450 (CYP)-dependent pathway [1, 2]. The active 
thiol metabolite irreversibly binds to the P2Y12 ADP recep-
tor of the platelets, which results in the inhibition of platelet 
aggregation [1, 2].
Many clinical studies have shown that the antiplatelet re-
sponse to clopidogrel treatment has wide inter-individual 
variability, which may be associated with the poor clinical 
outcome in some patients [3-6]. Recent studies on the me-
chanisms associated with clopidogrel resistance have shown 
that genetic polymorphisms, noncompliance, inappropriate 
dosage, obesity, insulin resistance, and drug-drug interac-
tions might play an important role in the development of 
clopidogrel resistance [1, 2, 5, 7-9]. CYP variants involved 
in the metabolic activation of clopidogrel, such as CYP3A4, 
CYP3A5, and CYP2C19, might also play an important role 92     www.kjlm.org
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in clopidogrel resistance [1, 2, 5, 8]. The CYP2C19*2 and 
CYP2C19*3 variants have been reported to be significantly 
associated with clopidogrel resistance [1, 2, 4, 8]. The aim of 
this study was to investigate the frequency of clopidogrel re-
sistance in Korean patients with ACS and to evaluate the re-
lationship between the antiplatelet effects of clopidogrel and 
pharmacogenetic factors. The effects of clinical and phar-
macokinetic factors on clopidogrel resistance were also in-
vestigated.
MATERIALS AND METHODS
1. Patients
A total of 114 patients diagnosed with ACS at the Sam-
sung Medical Center between June 2008 and July 2009 were 
evaluated. All the patients underwent coronary angiography 
and received a daily dose of 75 mg (105 patients) or 150 mg 
(9 patients) of clopidogrel for more than a month. The ages 
of the patients ranged from 35 to 87 yr (median age, 63 yr) 
and their body weights ranged from 43 to 105 kg (median 
weight, 69 kg). All the patients were undergoing dual anti-
platelet therapy with aspirin and clopidogrel. Of the 114 pa-
tients, 32 received an additional dose of cilostazol. This 
study was approved by the Institutional Review Board of 
Samsung Medical Center, Seoul, Korea. Written informed 
consent was provided by all the patients.
2. Estimation of the concentration of clopidogrel
All blood samples were collected at a steady state before 
the next administration of clopidogrel. The plasma concen-
trations of clopidogrel were determined using HPLC (HPLC 
1100 system; Agilent, Santa Clara, CA , USA) coupled with 
tandem mass spectrometry (MS/MS) (API 4000; Applied 
Biosystems, Foster City, CA, USA). Chromatographic sepa-
ration was performed on a C18 column (2.1×50 mm, 3 μm, 
Atlantis dC18, Waters; Milford, MA, USA). The mobile phase 
consisted of deionized water and acetonitrile with 0.1% for-
mic acid, and the flow rate was 0.25 mL/min. The mass 
spectrometry analysis was performed in the multiple reac-
tion monitoring mode, where the precursor-to-product ion 
transition was monitored at mass-to-charge ratio (m/z) 
322.1→212.1 for clopidogrel and m/z 326.1→216.1 for the 
internal standard (
2H4-clopidogrel). The CV values for in-
tra- and inter-day precision were less than 10%, and the cal-
ibration curve ranged from 1 to 1,000 pg/mL.
3. Evaluation of the antiplatelet effects of clopidogrel
The platelet function test was performed to monitor the 
antiplatelet effects of clopidogrel. The degree of platelet inhi-
bition was determined by the VerifyNow P2Y12 assay (Ac-
cumetrics, San Diego, CA, USA). Data on ADP-induced 
platelet aggregation and clopidogrel-induced platelet inhibi-
tion were expressed in terms of platelet reactivity units and 
percent inhibition, respectively.
4. CYP2C19 genotyping
Genomic DNA was extracted from whole-blood leuko-
cytes by using the Wizard Genomic DNA Purification Kit 
(Promega, Madison, WI, USA). Exon 4 and exon 5 of the 
CYP2C19 gene were isolated; CYP2C19*2 (681G>A; rs42-
44285) and CYP2C19*3 (636G>A; rs4986893) were ampli-
fied using PCR and a thermal cycler (Model 9700; Applied 
Biosystems). After treatment with shrimp alkaline phospha-
tase and exonuclease I, direct sequencing was performed 
using an ABI Prism 3100 Genetic Analyzer (Applied Biosys-
tems) with a BigDye Terminator Cycle Sequencing Ready 
Reaction Kit (Applied Biosystems).
5. Statistical analysis
All statistical analyses were performed using MedCalc 
(MedCalc software; Mariakerke, Belgium). The findings for 
the non-responder and responder groups were compared 
using the Chi-square and Mann-Whitney tests. P values 
less than 0.05 were considered statistically significant.
RESULTS
Among the 114 patients evaluated in this study, 68 (60%) 
were carriers for the CYP2C19*2 or CYP2C19*3 (Table 1). 
Table 1. Comparison of responders and non-responders
Group
Responders Non-responders
P value
(N=58; 51%) (N=56; 49%)
Age (yr) 64
(35-83)
63
(37-87)
0.948
Sex (M/F) 43:15 48:8 0.104
Cilostazol use (N) 17 15 0.836
Use of CYP2C19 inhibitors (N) 10 7 0.601
Use of CYP3A inhibitors (N) 13 18 0.400
Use of CYP3A inducers (N) 45 43 0.810
Clopidogrel dose/weight (mg/kg) 1.11
(0.82-1.57)
1.09
(0.71-3.0)
0.389
Diabetes mellitus (N) 11 13 0.819
Clopidogrel conc. (pg/mL) 51.4
(2.4-1,604)
43.1
(1.0-1,717)
0.654
CYP2C19*2 or *3 carrier (N) 40%
(23/58)
80%
(45/56)
<0.0001
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There was a wide inter-individual variability in platelet in-
hibition (0-76%), and 56 patients (49%) showed less than 
20% inhibition. Non-responders to clopidogrel treatment 
were more frequently found among patients with the vari-
ant CYP2C19 genes (P value<0.0001) (Table 1 and Fig. 1).
Clopidogrel concentrations ranged from 1 to 1,717 pg/
mL (median, 39.5 pg/mL). There was no correlation be-
tween clopidogrel concentration and the weight-adjusted 
dose (data not shown). There was no difference between the 
clopidogrel concentrations in the responder and non-re-
sponder groups. Regarding the concentration of clopidogrel 
on the basis of the CYP2C19 genotype, the median concen-
trations of clopidogrel were 92.3 pg/mL and 34.1 pg/mL in 
patients with the wild-type and CYP2C19 variants, respec-
tively (P value=0.0574).
In addition, other factors such as diabetes mellitus (DM) 
and concurrent medications, such as CYP2C19 inhibitors, 
CYP3A inhibitors, or CYP3A inducers, did not differ be-
tween the 2 study groups.
DISCUSSION
The goal of the present study was to evaluate the frequency 
of clopidogrel resistance and to comprehensively investigate 
the clinical, pharmacokinetic, and pharmacogenetic factors 
associated with clopidogrel resistance in Korean patients 
with ACS. Clopidogrel resistance was observed in 53 pa-
tients (46%) with ACS in this study. The frequency of clopi-
dogrel resistance has been reported to range from 5% to 44% 
[8, 10, 11]. Clopidogrel resistance was believed to be caused 
by various clinical, pharmacokinetic, and pharmacogenetic 
factors [1, 2, 5, 7-9]. In this study, CYP2C19 genotypes were 
observed to have a significant association with clopidogrel 
resistance in Korean patients with coronary artery disease 
(CAD).
CYP2C19*2 is a mutation caused by the substitution of 
guanine with adenine at nucleotide position 681 of exon 5, 
which results in aberrant splicing and complete loss of CY-
P2C19 activity [2, 9]. CYP2C19*3 is a mutation caused by a 
guanine to adenine point mutation at nucleotide position 
636 of exon 4, which produces a premature stop codon [12]. 
Previous studies have suggested a correlation between CY-
P2C19*2 and clopidogrel resistance; however, most of these 
studies have been performed in patients from the Cauca-
sian region, and there is very limited data on Asian popula-
tions. A previous study reported that only the CYP2C19*3 
genotype was a significant risk factor for clopidogrel resis-
tance among Korean patients with the CYP1A1, CYP2A2, 
CYP3A4, CYP3A5, CYP2C19, CYP2J2, and P2RY12 geno-
types [8].
To investigate the pharmacokinetic factors associated 
with clopidogrel resistance, we quantified the plasma con-
centration of the prodrug clopidogrel. In procedures for 
quantification of active metabolites, a stabilization protocol 
for the unstable compounds is required [13, 14]. Although 
the use of special techniques for stabilizing the active me-
tabolites was not possible in a routine clinical setting, high 
concentrations of the prodrug clopidogrel most likely indi-
cated low rates of conversion of the prodrug to the active 
metabolite; thus, the antiplatelet effects were expected to be 
minimal in patients with high concentrations of clopido-
grel. Patients who received clopidogrel therapy showed a 
wide distribution of clopidogrel concentrations. However, 
there was no correlation between the concentration and the 
weight-adjusted dose. Clopidogrel concentrations showed 
no correlation with other factors such as percent inhibition 
of platelets and CYP2C19 variants. The possible reasons for 
the lack of difference in clopidogrel concentrations on the 
basis of the CYP2C19 genotype are as follows: the potential 
effects of genetic polymorphisms other than CYP2C19; var-
ious clinical factors such as compliance, obesity, DM, and 
underlying characteristics of CAD; measurement of the 
prodrug clopidogrel concentration, which acted an indirect 
surrogate marker, rather than the active metabolite concen-
tration; the factors associated with the sampling time for 
drug monitoring; and the small number of study subjects.
Pharmacodynamic response to clopidogrel was dimin-
ished by the genetic variations, but an association between 
the CYP2C19 genotype and clopidogrel concentrations was 
not observed in this study. Only 15% of clopidogrel is con-
Fig. 1. Comparison of the percentage inhibition of platelet aggregation and 
CYP2C19 polymorphisms.
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verted to active thiol metabolites by the CYP enzymes, while 
the remaining 85% is converted to inactive metabolites by 
esterases [5]. In addition, the levels of the prodrug clopido-
grel were extremely low in comparison with the levels of the 
active and inactive metabolites. Other genes associated with 
absorption (ABCB1) and activation (CYP3A5) could also 
influence clopidogrel concentration. The possibility of the 
metabolic pathways influencing the clopidogrel response 
cannot be excluded. We also evaluated the possibility of 
drug-drug interactions leading to differences in the phar-
macokinetic and pharmacodynamic characteristics of clopi-
dogrel. Concurrent medications, such as CYP3A inducers 
or inhibitors, were not associated with the clopidogrel con-
centration or clopidogrel resistance. The clinical factors as-
sociated with clopidogrel resistance include noncompliance 
and insulin resistance [1]. Patients with DM have been re-
ported to have significantly lower levels of active metabolites 
[1]. However, the 24 patients with DM who were on medi-
cation did not show differences in clopidogrel response in 
this study.
The study had the following limitations: First, only 2 al-
lelic variants of CYP2C19 were studied. Other genes in the 
CYP group might also be involved in the metabolism of 
clopidogrel [1, 2, 7, 9]. Second, the plasma concentrations 
of the active thiol metabolites were not measured. Third, 
the number of patients was small.
In conclusion, this is the first study to evaluate the clini-
cal, pharmacokinetic, and pharmacogenetic characteristics 
of clopidogrel resistance in Korean patients with ACS; the 
evaluations included the monitoring of clopidogrel concen-
trations. The results of this study confirmed that the genetic 
polymorphism of CYP2C19 could be important in clopido-
grel response. However, further studies are required to in-
vestigate other likely factors involved in clopidogrel resis-
tance.
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